Lenvatinib

Lenvatinib is a member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. Among its listed roles, it functions as a vascular endothelial growth factor receptor antagonist, an orphan drug, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and a fibroblast growth factor receptor antagonist. It belongs to the class of quinolines, an aromatic ether, a monocarboxylic acid amide, an aromatic amide, a member of monochlorobenzenes, a member of cyclopropanes and a member of phenylureas. It is the conjugate base of lenvatinib(1+). It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and VEGF inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lenvatinibum and Lenvatini. Its PubChem CID is 9823820.